Ann: Appointment of VP Clinical Operations & Data Management, page-8

Started buying in March this year. There's just too much going on with its current and upcoming clinical trials. Management comes across as very ambitious and despite the weak SP, keeps moving forward when other companies are too busy complaining and whinging about changing market conditions and/or impatient shareholders. There'll be plenty to talk about here short, medium and long term. Looking at Century Therapeutics for example (US based, early-stage biotech company utilizing iNK and iT cell platforms, pre any IND submission), you quickly realise what the MC could be like - spoiler: it is not A$40 million.